Delivery Order SPE2DR25D3202-SPE2DR26F8D7M
Award Date 11/18/25
Potential Completion Date 11/19/25
Potential Value $9.1K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order valued at $15,740.52 to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) Pen 40 mg/0.4 mL, a biologic immunosuppressant medication used to treat rheumatoid arthritis and other inflammatory conditions. This competitively awarded, firm fixed-price delivery order was issued on November 13, 2025, with an ultimate completion date of November 14, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on November 18, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a biologic immunosuppressant medication used to treat rheumatoid arthritis and other inflammatory conditions. The order, valued at $2,387.94 with a firm fixed price structure, will be fulfilled from the contractor's Conshohocken, Pennsylvania facility and is scheduled for completion by November 19, 2025. This is a non-set-aside...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 15, 2025, for the supply of HUMIRA (Adalimumab) Pen 40 mg/0.4 mL, a biologic immunosuppressant medication used to treat rheumatoid arthritis and other autoimmune conditions. This firm fixed-price delivery order, valued at $8,435.70, represents an uncompeted non-set-aside award and is scheduled for completion by July 16, 2025. The contract will be fulfilled from AmerisourceBergen's distribution...
- The Defense Logistics Agency awarded a delivery order valued at $53,776.82 to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) pen 40 mg/0.4 mL, a biologic medication used primarily for rheumatoid arthritis and other autoimmune conditions. This firm fixed-price delivery order, awarded on September 9, 2025, with an ultimate completion date of September 10, 2025, represents a non-competitive set-aside procurement conducted under the company's existing Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a $15,863.44 delivery order to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) prefilled pens at 40 mg/0.4 mL, a biologic immunosuppressant medication commonly used to treat rheumatoid arthritis and other autoimmune conditions. The contract utilizes firm fixed pricing with no set-aside designation and is scheduled for completion by November 13, 2025. The pharmaceutical product will be delivered to the company's facility in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a delivery order valued at $1,953.33 to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) Pen 40 mg/0.4 mL, a biologic immunosuppressant medication used to treat autoimmune conditions. The contract is a firm fixed-price delivery order with an ultimate completion date of September 24, 2025, and was awarded on a competitive, non-set-aside basis. Performance will take place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,759.98 to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) Pen 80 mg/0.8 mL, a biologic immunosuppressant medication used to treat autoimmune conditions. This is a firm fixed-price, competitively awarded contract with no set-aside designation, with an ultimate completion date of November 12, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the...
- AmerisourceBergen Drug Corp has been awarded a delivery order by the Defense Logistics Agency Medical Supply Chain for $34,644.30 to supply HUMIRA (adalimumab) CF Pen 40 mg/0.4 mL, a biologic immunosuppressant medication used to treat rheumatoid arthritis and other autoimmune conditions. The award, issued on July 15, 2025, with completion targeted for July 16, 2025, employs a firm fixed price structure with no set-aside designation, indicating competitive award selection. The contract will be...
- The Defense Logistics Agency awarded a delivery order valued at $10,983.76 to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) Pen 80 mg/0.8 mL, a biologic immunosuppressant medication used to treat autoimmune conditions including rheumatoid arthritis, Crohn's disease, and ulcerative colitis. This firm fixed-price delivery order, awarded on August 14, 2025, with an ultimate completion date of August 15, 2025, represents a routine pharmaceutical supply transaction supporting federal healthcare...
- The Defense Logistics Agency awarded a delivery order valued at $3,021.24 to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) Pen 80 mg/0.8 mL, a biologic medication commonly used to treat rheumatoid arthritis, psoriasis, and other inflammatory conditions. This firm fixed-price, non-set-aside contract was awarded on September 2, 2025, with an ultimate completion date of September 3, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The...